Xavier Thomas

27.9k total citations · 1 hit paper
414 papers, 11.9k citations indexed

About

Xavier Thomas is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Molecular Biology. According to data from OpenAlex, Xavier Thomas has authored 414 papers receiving a total of 11.9k indexed citations (citations by other indexed papers that have themselves been cited), including 275 papers in Hematology, 151 papers in Public Health, Environmental and Occupational Health and 101 papers in Molecular Biology. Recurrent topics in Xavier Thomas's work include Acute Myeloid Leukemia Research (209 papers), Acute Lymphoblastic Leukemia research (150 papers) and Chronic Myeloid Leukemia Treatments (76 papers). Xavier Thomas is often cited by papers focused on Acute Myeloid Leukemia Research (209 papers), Acute Lymphoblastic Leukemia research (150 papers) and Chronic Myeloid Leukemia Treatments (76 papers). Xavier Thomas collaborates with scholars based in France, United States and Belgium. Xavier Thomas's co-authors include Hervé Dombret, Emmanuel Raffoux, Françoise Huguet, E Archimbaud, D Fière, Pierre Fenaux, Stéphane de Botton, Claude Preudhomme, Véronique Lhéritier and Sylvie Castaigné and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Xavier Thomas

408 papers receiving 11.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

2012 818 citations Hagop M. Kantarjian, Xavier Thomas et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Xavier Thomas

Since Specialization

Citations

This map shows the geographic impact of Xavier Thomas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xavier Thomas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xavier Thomas more than expected).

Fields of papers citing papers by Xavier Thomas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xavier Thomas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xavier Thomas. The network helps show where Xavier Thomas may publish in the future.

Co-authorship network of co-authors of Xavier Thomas

This figure shows the co-authorship network connecting the top 25 collaborators of Xavier Thomas. A scholar is included among the top collaborators of Xavier Thomas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xavier Thomas. Xavier Thomas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Promising Drugs Targeting Specific Mechanisms of Deregulation in T Cell Lineage Acute Lymphoblastic Leukemia 2025 ·Oncology and Therapy ·Xavier Thomas	1
2	Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA study 2024 ·Blood Cancer Journal ·Pierre Hirsch, Jérôme Lambert, Maxime Bucci, Caroline Deswarte, (unknown), Juliette Lambert, Laurène Fenwarth, Jean‐Baptiste Micol, Christine Terré, Karine Celli‐Lebras, Xavier Thomas, Hervé Dombret, Nicolas Duployez, Claude Preudhomme, Raphaël Itzykson, François Delhommeau	3
3	Impact on Outcome of Minimal Residual Disease after Hematopoietic Stem Cell Transplantation with Fludarabine, Amsacrine, and Cytosine Arabinoside-Busulfan Conditioning: A Retrospective Monocentric Study 2022 ·Transplantation and Cellular Therapy ·(unknown), Adriana Pleșa, (unknown), Gaëlle Fossard, Fiorenza Barraco, (unknown), Marie Balsat, Sophie Ducastelle-Leprêtre, Lila Gilis, Xavier Thomas, Hervé Ghesquières, Isabelle Tigaud, Sandrine Hayette, Sarah Huet, Pierre Sujobert, (unknown), (unknown), Mauricette Michallet, Hélène Labussière‐Wallet, Maël Heiblig	4
4	Epigenetic Silencing Affects l -Asparaginase Sensitivity and Predicts Outcome in T-ALL 2019 ·Clinical Cancer Research ·Aurore Touzart, Étienne Lengliné, (unknown), Mohamed Belhocine, (unknown), Xavier Thomas, Salvatore Spicuglia, Denis Puthier, Françoise Pflumio, Thibaut Leguay, Carlos Graux, Yves Chalandon, Françoise Huguet, Stéphane Leprêtre, Norbert Ifrah, Hervé Dombret, Elizabeth Macintyre, Mathilde Hunault, Nicolas Boissel, Vahid Asnafi	28
5	Efficiency of blinatumomab in a t(8;21) acute myeloid leukemia expressing CD19 2019 ·Haematologica ·Adriana Pleșa, Hélène Labussière‐Wallet, Sandrine Hayette, Gilles Salles, Xavier Thomas, Pierre Sujobert	5
6	Patient-Reported Disease Burden in the Elderly Patients with Acute Myeloid Leukemia 2017 ·Blood ·(unknown), Jianming He, Liang Xiu, (unknown), (unknown), Xavier Thomas	2
7	Prevention of Dysbiosis Complications with Autologous Fecal Microbiota Transplantation (auto-FMT) in Acute Myeloid Leukemia (AML) Patients Undergoing Intensive Treatment (ODYSSEE study): First Results of a Prospective Multicenter Trial 2017 ·Blood ·Mohamad Mohty, Florent Malard, Evelyne D’Incan, Xavier Thomas, Christian Récher, Anne‐Sophie Michallet, Pierre Péterlin, Anne Vekhoff, Norbert Vey, (unknown), Philippe Lehert, Joël Doré, Ollivier Legrand	5
8	The safety of treatment options for elderly people with acute myeloid leukemia 2016 ·Expert Opinion on Drug Safety ·Xavier Thomas, (unknown)	2
9	Novel approaches to pediatric leukemia treatment 2015 ·Expert Review of Anticancer Therapy ·Xavier Thomas	2
10	A Post Hoc Sensitivity Analysis of Survival Probabilities in a Multinational Phase III Trial of Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia 2013 ·Clinical Lymphoma Myeloma & Leukemia ·Xavier Thomas, Christopher Arthur, Jacques Delaunay, Mark M. Jones, (unknown), Hagop M. Kantarjian	17
11	Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia breakdown → 2012 ·Journal of Clinical Oncology ·Hagop M. Kantarjian, Xavier Thomas, Anna Dmoszyńska, Agnieszka Wierzbowska, Grzegorz Mazur, Jiří Mayer, Jyh-Pyng Gau, Wen‐Chien Chou, Rena Buckstein, Jaroslav Čermák, Ching-Yuan Kuo, Albert Oriol, Farhad Ravandi, Stefan Faderl, Jacques Delaunay, Daniel Lysák, Mark D. Minden, Christopher Arthur	818
12	Outcome of Acute Promyelocytic Leukemia (APL) in Children and Adolescents: An Analysis in Two Consecutive Trials of the European APL Group 2012 ·Journal of Clinical Oncology ·Cécile Bally, Jehane Fadlallah, Guy Leverger, Yves Bertrand, Alain Robert, André Baruchel, Agnès Guerci, Christian Récher, Emmanuel Raffoux, Xavier Thomas, Thierry Leblanc, Nadia Idres, Bruno Cassinat, Norbert Vey, Christine Chomienne, Hervé Dombret, Miguel Á. Sanz, Pierre Fenaux, Lionel Adès	32
13	[Acute lymphoblastic leukemia with Philadelphia chromosome: treatment with kinase inhibitors]. 2007 ·PubMed ·Xavier Thomas	1
14	High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group 2006 ·Leukemia ·A.-L. Taksin, Ollivier Legrand, Emmanuel Raffoux, Thierry de Revel, Xavier Thomas, Nathalie Contentin, Réda Bouabdallah, Cécile Pautas, Pascal Turlure, Oumédaly Reman, Claude Gardin, Bruno Varet, Stéphane de Botton, (unknown), H. Farhat, Sylvie Chevret, Hervé Dombret, Sylvie Castaigné	226
15	Stratégies thérapeutiques actuelles dans les leucémies aiguës lymphoblastiques de l‘adulte 2003 ·Bulletin du Cancer ·Xavier Thomas, Quoc‐Hung Le	3
16	Traitement des leucémies aiguës myéloïdes de l'adulte en rechute 2002 ·Bulletin du Cancer ·Xavier Thomas, Quoc‐Hung Le	1
17	Prospective, karyotype analysis in adult acute lymphoblastic leukemia: A LALA group (French-Belgium-Switzerland) report of 730 cases 2002 ·Blood ·C Charrin, Nicole Dastugue, (unknown), (unknown), M Jotterand-Bellomo, Christian Bastard, (unknown), (unknown), Sylvie Taviaux, JL Laï, (unknown), D Fière, Xavier Thomas	2
18	No Superiority of Autologous Stem Cell Transplantation over Chemotherapy Alone in Adult Ph-Negative ALL in First Complete Remission A Long Follow-Up Report Combining Results of LALA 85, 87 and 94 Trials 2002 ·Blood ·Nathalie Dhédin, Xavier Thomas, F. Huguet, Véronique Lhéritier, Jean-Michel Boiron, (unknown), Norbert Vey, Mathieu Kuentz, (unknown), Claude Boucheix, J Gäbert, D Fière, Vernant Jp	2
19	Interdependence between Cytokines and Cell Adhesion Molecules to Induce Interleukin-6 Production by Stromal Cells in Myeloma 1998 ·Leukemia & lymphoma ·Xavier Thomas, Bruno Anglaret, Jean‐Pierre Magaud, Joshua Epstein, E Archimbaud	34
20	Molecular analysis of cyclin-dependent kinase inhibitors in human leukemias 1997 ·Leukemia ·Sandrine Hayette, Xavier Thomas, Y. Bertrand, Isabelle Tigaud, Mary Callanan, Anne Thiébaut, C Charrin, E Archimbaud, J.P. Magaud, Ruth Rimokh	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact